Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06544109
PHASE2/PHASE3

Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

Sponsor: The First Affiliated Hospital of Soochow University

View on ClinicalTrials.gov

Summary

This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.

Official title: Venetoclax for Prevention of Differentiation Syndrom (DS) in Acute Promyelocytic Leukemia (APL) Patients : An Open-lable, Single-arm, Multicenter, Phase Ⅱ Clinical Trail

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

98

Start Date

2023-08-01

Completion Date

2028-08-01

Last Updated

2024-08-09

Healthy Volunteers

No

Interventions

DRUG

venetoclax

patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax

Locations (1)

Qiu huiying

Suzhou, Jiangsu, China